Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc., a foreign private issuer, on March 2, 2017. The filing serves to report a material change pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The document incorporates a Material Change Report dated March 2, 2017, as Exhibit 99.1, and is incorporated by reference into the Registrant's Registration Statement on Form F-10 (File No. 333-206994).
Key Financial Metrics
The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document.
Material Changes
The filing explicitly references a "Material Change Report" dated March 2, 2017, as Exhibit 99.1. However, the text of the Form 6-K itself does not describe the specific nature of the material change, only that it exists and is attached as an exhibit.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, specific risks, contingencies, or details regarding unusual items. The document is a procedural cover sheet for the attached exhibit.
Investor Verification Checklist
- Review Exhibit 99.1 (Material Change Report) to understand the specific event triggering this filing.
- Verify the details of the Material Change Report against the company's Form F-10 Registration Statement (File No. 333-206994).
- Confirm the identity of the signatory, Dennis Bourgeault, as the Chief Financial Officer.